Physician profile
Peter Lerza
NPI 1316591647
$2,226.33
in general payments reported to CMS, 2019-2025
25 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $474 · 2023: $251 · 2024: $877 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.12 | 2021-2025 | |
| Lilly USA, LLC | $314.63 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $277.28 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $187.62 | 2021 | |
| Pfizer INC. | $144.73 | 2024-2025 | |
| Amgen INC. | $114.13 | 2024 | Otezla, Repatha, Krystexxa |
| Exact Sciences Corporation | $105.76 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $91.25 | 2024-2025 | |
| Medtronic, INC. | $83.92 | 2022-2024 | Intellis Adaptivestim |
| Astellas Pharma US INC | $80.10 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $64.22 | 2022-2024 | |
| Organogenesis INC. | $62.29 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $45.50 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $45.05 | 2024-2025 | Breztri |
| Watermark Medical, INC. | $30.83 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.35 | 2022 | |
| Dexcom, INC. | $25.00 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.36 | 2023 | Jardiance, Tradjenta |
| Tris Pharma INC | $17.50 | 2022 | |
| Resmed Corp | $16.31 | 2024 | |
| Corcept Therapeutics | $15.79 | 2022 | |
| Medicomp INC | $15.16 | 2024 | Telepatch Cardiac Monitor |
| Mylan Specialty L.P. | $12.68 | 2022 | |
| Currax Pharmaceuticals LLC | $12.31 | 2021 | |
| Organon LLC | $11.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lerza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.